AZN : TROPION Analysis Reveals Datopotamab Deruxtecan Efficacy In Advanced EGFR-Mutated Lung Cancer

(RTTNews) - A pooled analysis of the TROPION-Lung05 phase 2 and the TROPION-Lung01 phase 3 trials showed that Daiichi Sankyo (DSKYF.PK) and AstraZeneca's (AZN, AZN.L) datopotamab deruxtecan (Dato-DXd) demonstrated clinically meaningful tumor response in patients with previously t https://www.nasdaq.com/articles/azn-tropion-analysis-reveals-datopotamab-deruxtecan-efficacy-advanced-egfr-mutated-lung